Eli Lilly licenses preclinical antisense program designed to treat ALS, dementia

Eli Lilly added another neuroscience program to its pipeline, licensing an antisense oligonucleotide from the ALS biotech QurAlis.

The deal, announced Monday, is the latest …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Manufacturing roundup: Aurisco completes FDA inspection of ingredient production site; NIH picks Exothera to develop nasal Covid vaccine

Aurisco Pharmaceutical said Tuesday that the FDA gave it the green light to produce active pharmaceutical ingredients (APIs) at a manufacturing site in Yangzhou, China.

August 18, 2023

Dexcom targets 25M Americans with new CGM aimed at non-insulin-using diabetics

Dive Brief: Dexcom next year will introduce a continuous glucose monitor aimed at the 25 million non-insulin-using Americans with Type 2 diabetes. The CGM, which is based

June 26, 2023

Cardiac Arrest Drug Administration Route a Toss Up

Intraosseous vascular access for the administration of epinephrine during out-of-hospital cardiac arrest wasn’t better than going for the veins first, two separate randomized trials showed.

November 1, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.